Table 1 |
|
|
Primers used |
|
|
Gene |
Primer |
|
|
|
|
IFN-γ |
Forward: 5'-CAT TGA AAG CCT AGA AAG TCT GAA TAA C-3' |
|
Reverse: 5'-TGG CTC TGC AGG ATT TTC ATG-3' |
|
|
BlyS |
Forward: 5'-CAG GAA CAG ACG CGC GAT TTC-3' |
|
Reverse: 5'-GTT GAG AAT GGC GGC ATC C-3' |
|
|
TRAIL |
Forward: 5'-GAT CAC TCG GAG AAG CAA CTC A-3' |
|
Reverse: 5'-GAG AGG ACT CCC AGG ATT CAA TG-3' |
|
|
TWEAK |
Forward: 5'-CGA GCT ATT GCA GCC CAT TAT-3' |
|
Reverse: 5'-ACC TGC TTG TGC TCC ATC CT-3' |
|
|
FasL |
Forward: 5'-GCA CAT AGC CAA CCC CAG TAC AC-3' |
|
Reverse: 5'-GCC ACC TTT ATT ATA CTT CAC TCC AG-3' |
|
|
|
|
|
BlyS, B lymphocyte stimulator; FasL, Fas ligand; IFN, interferon; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand; TWEAK, tumor necrosis factor-like weak inducer of apoptosis. |
|
|
Monrad et al. Arthritis Research & Therapy 2008 10:R5 doi:10.1186/ar2353 |
|